Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Sep 12, 2023 1:11pm
197 Views
Post# 35631864

RE:RE:Oh well fun is over

RE:RE:Oh well fun is over The stock's price should logically move higher since a reverse split signifies no actual change and there has been the following good news since then:

The TH-1902 trial has restarted

THTX has more cash than the Marathon loan terms require much earlier than expected

THTX went into a positive cash flow mode earlier than anticipated 

Those are 3 big pieces of positive news, especially considering the risk of bankruptcy many seemed to be errantly presuming before that news. 

So, if life were fair, THTX's stock price should recover to a level higher than before the reverse split. That could be as much as 100% upside from here. Logically, that is where it should be headed. 


Wino115 wrote: Honestly, we knew a correction would have to come given the absolutely massive vols and triple-digit rise in the price. It was inevitable, but doesn't necessarily mean it's over and could be indegestion.  Still only at $.50 pre consolidation, so way off. Will be volatile now for a while given what's happened.


<< Previous
Bullboard Posts
Next >>